Humacyte terminates Revenue Interest Purchase Agreement; pays $38M cash + 5.7M shares to purchasers

Humacyte, Inc.

Terminated Revenue Interest Purchase Agreement and Option Agreement with TPC Investments LP and Hook SA LLC as of Dec 15, 2025.
Consideration: $38 million cash (funded via new credit facility) plus 5,725,190 shares of common stock in a registered direct offering.
Offering closes Dec 15, 2025; shares issued under effective shelf registration statement (File No. 333-290231).
Company expects to fund $38M cash payment from proceeds of a new credit facility.
Satisfaction of all obligations under terminated agreements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.